ASH 2005
American Society of Hematology Annual Meeting
Interviews and expert commentary from ASH 2005 — study authors and key opinion leaders discuss the findings and their clinical implications.
Audio Journal of Oncology 14.2, March 2006
Reporting from: American Society of Hematology Meeting, Atlanta, 10-13 December 2005 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Gordon McVie, European Institute of Oncol
Audio Journal of Hematologic Malignancy, Volume 2 Number 1
Reporting from: American Society of Hematology Meeting, Philadelphia, December 6-10, 2002 Scientific Editors: George Canellos, Dana-Farber Cancer Institute, Boston Anton Hagenbeek, University of Utrec
Rituximab Maintenance after Chemotherapy Gives Better Outcomes in Advanced Follicular Lymphoma
Sandra Horning Abstract 349 Sandra Horning, Stanford University Medical Center It is not necessary to use rituximab along with standard CVP (cyclophosphamide, vincristine, predinsone) induction therap
Targeted Therapies in Multiple Myeloma Treatment Decisions
Vincent Rajkumar Vincent Rajkumar, Divison of Hematology, Mayo Clinic At a section of the hematology meeting talking about newly diagnosed multiple myeloma and the evolving treatments, Vincent Rajkuma
Pro-Apoptosis, mTOR Pathways: New Targets for Lymphoma
Owen O’Connor Owen O’Connor, Memorial Sloan-Kettering Cancer Center, New York Owen O’Connor also gave data from early, two studies: one looking at treating lymphoma with the drug SAH